403 related articles for article (PubMed ID: 16903863)
1. Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission.
Andersson DR; Nissbrandt H; Bergquist F
Eur J Neurosci; 2006 Jul; 24(2):617-24. PubMed ID: 16903863
[TBL] [Abstract][Full Text] [Related]
2. Motor activity-induced dopamine release in the substantia nigra is regulated by muscarinic receptors.
Andersson DR; Björnsson E; Bergquist F; Nissbrandt H
Exp Neurol; 2010 Jan; 221(1):251-9. PubMed ID: 19944096
[TBL] [Abstract][Full Text] [Related]
3. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK
Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381
[TBL] [Abstract][Full Text] [Related]
4. Striatal dysfunction increases basal ganglia output during motor cortex activation in parkinsonian rats.
Belluscio MA; Riquelme LA; Murer MG
Eur J Neurosci; 2007 May; 25(9):2791-804. PubMed ID: 17561844
[TBL] [Abstract][Full Text] [Related]
5. Modulation of dopamine release by striatal 5-HT2C receptors.
Alex KD; Yavanian GJ; McFarlane HG; Pluto CP; Pehek EA
Synapse; 2005 Mar; 55(4):242-51. PubMed ID: 15668911
[TBL] [Abstract][Full Text] [Related]
6. Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition.
McArthur S; Murray HE; Dhankot A; Dexter DT; Gillies GE
J Neurochem; 2007 Feb; 100(3):678-92. PubMed ID: 17116232
[TBL] [Abstract][Full Text] [Related]
7. Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: release from adrenergic terminals and modulation by alpha2-autoreceptors.
Gobert A; Billiras R; Cistarelli L; Millan MJ
J Neurosci Methods; 2004 Dec; 140(1-2):141-52. PubMed ID: 15589344
[TBL] [Abstract][Full Text] [Related]
8. Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson's disease, the MPTP-intoxicated mouse.
Chassain C; Bielicki G; Durand E; Lolignier S; Essafi F; Traoré A; Durif F
J Neurochem; 2008 May; 105(3):874-82. PubMed ID: 18088356
[TBL] [Abstract][Full Text] [Related]
9. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity.
Gaugler MN; Genc O; Bobela W; Mohanna S; Ardah MT; El-Agnaf OM; Cantoni M; Bensadoun JC; Schneggenburger R; Knott GW; Aebischer P; Schneider BL
Acta Neuropathol; 2012 May; 123(5):653-69. PubMed ID: 22361813
[TBL] [Abstract][Full Text] [Related]
10. Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson's disease.
Ogura T; Ogata M; Akita H; Jitsuki S; Akiba L; Noda K; Hoka S; Saji M
Neurosci Res; 2005 Mar; 51(3):299-308. PubMed ID: 15710494
[TBL] [Abstract][Full Text] [Related]
11. Single administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline increases the extracellular concentration of dopamine in rat striatum.
Katagiri N; Abe K; Kitabatake M; Utsunomiya I; Horiguchi Y; Hoshi K; Taguchi K
Neuroscience; 2009 Jun; 160(4):820-8. PubMed ID: 19285542
[TBL] [Abstract][Full Text] [Related]
12. Partial dopamine loss enhances activated caspase-3 activity: differential outcomes in striatal projection systems.
Ariano MA; Grissell AE; Littlejohn FC; Buchanan TM; Elsworth JD; Collier TJ; Steece-Collier K
J Neurosci Res; 2005 Nov; 82(3):387-96. PubMed ID: 16180225
[TBL] [Abstract][Full Text] [Related]
13. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra.
Yamamoto BK; Nash JF; Gudelsky GA
J Pharmacol Exp Ther; 1995 Jun; 273(3):1063-70. PubMed ID: 7791076
[TBL] [Abstract][Full Text] [Related]
14. Nigral injection of antisense oligonucleotides to synaptotagmin I using HVJ-liposome vectors causes disruption of dopamine release in the striatum and impaired skill learning.
Akita H; Ogata M; Jitsuki S; Ogura T; Oh-Nishi A; Hoka S; Saji M
Brain Res; 2006 Jun; 1095(1):178-89. PubMed ID: 16729982
[TBL] [Abstract][Full Text] [Related]
15. The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats.
Konieczny J; Wardas J; Kuter K; Pilc A; Ossowska K
Neuroscience; 2007 Mar; 145(2):611-20. PubMed ID: 17224239
[TBL] [Abstract][Full Text] [Related]
16. Exogenous l-DOPA induce no dopamine immuno-reactivity in striatal astroglias and microglias of adult rats with extensive nigro-striatal dopaminergic denervation.
Maeda T; Nagata K; Yoshida Y
Neurosci Lett; 2008 Mar; 433(3):255-8. PubMed ID: 18255227
[TBL] [Abstract][Full Text] [Related]
17. CGP 56999A, a GABA(B) receptor antagonist, enhances expression of brain-derived neurotrophic factor and attenuates dopamine depletion in the rat corpus striatum following a 6-hydroxydopamine lesion of the nigrostriatal pathway.
Enna SJ; Reisman SA; Stanford JA
Neurosci Lett; 2006 Oct; 406(1-2):102-6. PubMed ID: 16890350
[TBL] [Abstract][Full Text] [Related]
18. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
Suzuki M; Desmond TJ; Albin RL; Frey KA
Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
[TBL] [Abstract][Full Text] [Related]
19. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.
Lee J; Zhu WM; Stanic D; Finkelstein DI; Horne MH; Henderson J; Lawrence AJ; O'Connor L; Tomas D; Drago J; Horne MK
Brain; 2008 Jun; 131(Pt 6):1574-87. PubMed ID: 18487277
[TBL] [Abstract][Full Text] [Related]
20. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.
Jourdain S; Morissette M; Morin N; Di Paolo T
J Neuroendocrinol; 2005 Aug; 17(8):509-17. PubMed ID: 16011487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
